GlaxoSmithKline's Strong Quarterly Profit Growth and Special Dividend Declaration

GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance. The company declared a special interim dividend and highlighted key product developments across various segments including pediatric and adult vaccines.

GlaxoSmithKline Pharmaceuticals announced a 16% year-on-year increase in its consolidated net profit, amounting to Rs 252 crore for the September quarter. This growth was fueled by strong sales across different segments, as stated in their latest regulatory filing on Tuesday.

Revenues also saw an upward trend, rising to Rs 1,010 crore compared to Rs 957 crore in the same period last year. The company declared a special interim dividend of Rs 12 per share in celebration of its centenary year in India, underlining its commitment to sustainable growth and innovation.

Key brands maintained their market share, with Augmentin leading the Indian pharma market and the respiratory portfolio gaining traction. The pediatric vaccine segment achieved double-digit growth, while the adult vaccines segment, notably Shingrix, advanced adult immunization in India. GSK Pharma's shares concluded the day slightly down at Rs 2,624.50 on BSE.

(With inputs from agencies.)